Statins: Benefit or risk?

Medicina Clinica

Volumn 118, Issue 9, 2002, Pages 335-336

  Capellà, Dolors ^a   Bosch, Montse ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE; MACROLIDE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ABDOMINAL DISEASE; ARTERIOSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MORBIDITY; MORTALITY; NAUSEA; SECONDARY PREVENTION; SPAIN; VOMITING; RISK FACTOR;

ANTILIPEMIC AGENTS; HUMANS; RISK FACTORS;

EID: 0037117263     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)72378-6     Document Type: Editorial

References (13)

1. Reflexiones sobre una retirada
2. Statin therapy-What now?
3. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
4. Estimation of contribution of changes in classic risk factors to trends in coronary-events rates across the WHO MONICA Project Populations
5. Serum total cholesterol and long-term coronary heart disease mortality in different cultures
6. The cost of inadequate prescriptions for hypolipidemic drugs
7. Growth in use of statins after trials is not targeted to most appropriate patients
8. Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials
9. HMG-CoA reductase inhibitors and myotoxicity
10. Learning from the cerivastatin experience
11. Consumo de hipolipemiantes en España, 1987-2000
12. Adjusting Europe's drug regulation to public health needs
13. Proactive safety surveillance